Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial-Reference-Cited by-全球学者库

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Published:2022-12 Issue:12 Volume:22 Page:1756-1768
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Zhao Fang-Hui,Wu Ting,Hu Yue-Mei,Wei Li-Hui,Li Ming-Qiang,Huang Wei-Jin,Chen Wen,Huang Shou-Jie,Pan Qin-Jing,Zhang Xun,Hong Ying,Zhao Chao,Li Qing,Chu Kai,Jiang Yun-Fei,Li Ming-Zhu,Tang Jie,Li Cai-Hong,Guo Dong-Ping,Ke Li-Dong,Wu Xin,Yao Xing-Mei,Nie Jian-Hui,Lin Bi-Zhen,Zhao Yu-Qian,Guo Meng,Zhao Jun,Zheng Feng-Zhu,Xu Xiao-Qian,Su Ying-Ying,Zhang Qiu-Fen,Sun Guang,Zhu Feng-Cai,Li Shao-Wei,Li Yi-Min,Pan Hui-Rong,Zhang Jun,Qiao You-Lin,Xia Ning-Shao

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference21 articles.

1. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis;Drolet;Lancet,2019

2. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019;Bruni;Prev Med,2021

3. Human papillomavirus vaccines: WHO position paper, May 2017;Wkly Epidemiol Rec,2017

4. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial;Qiao;J Natl Cancer Inst,2020

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody;Science Bulletin;2024-02

2. Virus‐like particles as powerful vaccination strategy against human viruses;Reviews in Medical Virology;2023-12-20

3. Prevalence and genotype distribution of HPV6/11/16/18 infections among 180,276 outpatient females from a Women’s and Children’s Central Hospital, 2015–2021, Chengdu, China;Scientific Reports;2023-12-14

4. Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis;Expert Review of Vaccines;2023-11-27

5. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial;The Lancet Infectious Diseases;2023-11